Emerging Treatment Paradigms in Colorectal Cancer: Opportunities and Risks
Oncology · Colorectal Cancer • Trial Update • Jun 2, 2026
Assessment confidence: 67% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.
Executive Thesis
The initiation of the COMMIT study represents a significant advancement in the treatment landscape for metastatic colorectal cancer, particularly for patients with DNA mismatch repair deficiency. The outcomes of this trial could redefine treatment protocols and enhance the competitive positioning of atezolizumab. Regulatory context from FDA (Oncology (Cancer)/Hematologic Malignancies Approval Notifications) supports the near-term read. Assessment grounded in 17 ranked evidence items (8 high-relevance).
Strategic Assessment
Success in this trial may enhance the market position of atezolizumab and influence treatment protocols for metastatic colorectal cancer. The strongest clinical anchor is Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (ClinicalTrials.gov), sub-indication match (colorectal cancer); entity match (atezolizumab). In colorectal cancer, 5 regulatory and 1 competitive items passed relevance filtering for Roche.
Competitive Pressure
The most relevant competitive pressure comes from Cardiff Oncology and Pfizer assess onvansertib in metastatic colorectal cancer trial (Humanexa Signals) — sub-indication match (colorectal cancer); entity match (metastatic colorectal cancer). This trial could position atezolizumab as a key treatment option in a competitive landscape dominated by existing chemotherapy regimens and emerging immunotherapies.
Regulatory Outlook
Regulatory risk is concentrated around Oncology (Cancer)/Hematologic Malignancies Approval Notifications (FDA). Entity match (oncology); Regulatory pathway relevance (approval). Positive trial results may lead to updated treatment guidelines and potential label expansions for atezolizumab, impacting its regulatory status and market access.
Key Risks
- Elevated medium regulatory exposure for Roche could delay market entry or constrain labeling if agency review intensifies.
- Signal severity is high — leadership review is warranted.
- Regulatory risk from FDA (Sunscreen: How to Help Protect Your Skin from the Sun) could weigh on Roche through agency review timelines and labeling constraints if follow-through weakens.
Key Opportunities
- If successful, the trial could significantly increase the market share of atezolizumab, positioning it as a preferred treatment option against established chemotherapy regimens and other emerging therapies.
- Upside for Roche may improve if Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (ClinicalTrials.gov) delivers favorable follow-through.
- Upside for Roche may improve if Lidocaine enhances antitumor effects of sorafenib and GW5074 in colorectal cancer cells. (PubMed) delivers favorable follow-through.
- FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
- Upside for Roche may improve if Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase o (ClinicalTrials.gov) delivers favorable follow-through.
What Would Change This Assessment
- This becomes more urgent if Monitor trial results and any announcements regarding interim analyses or changes in treatment guidelines based on findings.
- Timeline shift beyond mid term would change urgency.
- A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.
Supporting Evidence
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAmedium relevance
Entity match (oncology); Regulatory pathway relevance (approval)
FDA document
View sourceFDA AP — INQOVI (SUPPL)
FDAmedium relevance
Entity match (oncology); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — INQOVI (SUPPL)
FDAmedium relevance
Entity match (oncology); Regulatory pathway relevance (nda)
FDA document
View sourceJanus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDAmedium relevance
Sponsor/company relevance (Roche)
FDA document
View sourceSunscreen: How to Help Protect Your Skin from the Sun
FDAmedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
ClinicalTrials.govhigh relevance
Sub-indication match (colorectal cancer); Entity match (atezolizumab)
FDA document
View sourceTesting the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase o
ClinicalTrials.govmedium relevance
Entity match (oncology)
FDA document
View sourceTesting the Addition of New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
ClinicalTrials.govmedium relevance
Entity match (oncology)
FDA document
View sourceTesting the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
No evidence in this category.
Deep learning based on CD3 histological slides for prediction of colon cancer outcome: analysis of three international stage III colon cancer cohorts.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Sponsor/company relevance (Roche)
FDA document
View sourceRisk Factors, Cancer Types and Prognostic Significance of Second Primary Cancer After Early-, Intermediate- and Late-Onset Colorectal Cancer: A Retrospective Study in Chinese High-Volume Cancer Center
PubMedhigh relevance
Sub-indication match (colorectal cancer); Sponsor/company relevance (Roche)
FDA document
View sourceLidocaine enhances antitumor effects of sorafenib and GW5074 in colorectal cancer cells.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Sponsor/company relevance (Roche)
FDA document
View sourceDiscovery of a novel and potent KRAS(G12V)-targeting peptide with antiproliferative activity against colorectal cancer cells.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Sponsor/company relevance (Roche)
FDA document
View sourceGenetic variants of the transporter SLC22A4 affect the abundance and survival of Fusobacterium nucleatum in colorectal cancer.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Sponsor/company relevance (Roche)
FDA document
View sourceGut microbiota and diet in colorectal cancer: Converging determinants of carcinogenesis.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Sponsor/company relevance (Roche)
FDA document
View sourceTrial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Entity match (oncology)
FDA document
View source
Related Signals
- Chemoimmunotherapy Shows Promise in MSS Colorectal Cancer: Pooled Analysis Insights
Trial Update
- High-Intensity Thermal Stress Boosts NK-Cell Cytotoxicity in HCC
Trial Update
- Lidocaine enhances efficacy of sorafenib and GW5074 in colorectal cancer cell lines
Trial Update
- Gut Microbial Markers Linked to Immunotherapy Response in Melanoma Identified in Cross-Cohort Study
Trial Update
- Fruquintinib Study in Metastatic Colorectal Cancer Patients in Poland
Trial Update
- Phase Ib/II Trial of QLC5508 and QLH12016 in Advanced Prostate Cancer
Trial Update
- Phase III Trial of Atezolizumab with Chemotherapy for Metastatic Colorectal Cancer Initiated
Trial Update
- Trial Comparing Radiotherapy with Dual Immunotherapy in Locally Advanced Rectal Cancer
Trial Update
- Dabrafenib and Trametinib Rollover Study for Continued Patient Access
Trial Update
- Cardiff Oncology and Pfizer assess onvansertib in metastatic colorectal cancer trial
Trial Update
- ROBIN Trial to Explore RT Effects on Immune System in Rectal Cancer
Trial Update
- Study on Durvalumab, Bevacizumab, and TACE for Advanced Hepatocellular Carcinoma
Trial Update
- Study on Exercise Program's Impact on Quality of Life in Prostate Cancer Patients
Trial Update
- Trial Evaluates Pelvic Radiotherapy with ADT in Node Positive Prostate Cancer
Trial Update
- Calderasib and Pembrolizumab Study in KRAS G12C NSCLC Shows Promising Efficacy
Trial Update
- Phase II Trial Compares FOLFOX8 and mFOLFOX6 in Metastatic Colorectal Cancer
Trial Update
- Pfizer's ELREXFIO Shows Significant PFS Improvement in RRMM Patients
Trial Update
- CMP-001 and Nivolumab Show Promise in Advanced Melanoma Phase 2/3 Trial
Trial Update
- 5-Year Data Shows Intismeran Autogene + KEYTRUDA Reduces Melanoma Recurrence Risk by 49%
Trial Update
- Lilly's Retevmo shows 83% reduction in disease recurrence for early-stage RET fusion-positive lung cancer
Trial Update
- Merck's Sacituzumab Tirumotecan Shows OS and PFS Improvement in Endometrial Cancer Phase 3 Trial
Trial Update
- Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA in NSCLC
Trial Update
- Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Trial Update
- TALZENNA Plus XTANDI Shows 52% rPFS Improvement in Metastatic Prostate Cancer
Trial Update
- Pfizer’s BRAFTOVI Regimen Nearly Doubles Progression-Free Survival in mCRC
Trial Update
- Phase III Trial of TR115 vs Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma
Trial Update
- Trial on MRI-guided SBRT for Liver Metastases Aims to Establish Safe Dose Levels
Trial Update
- MRI-Guided Radiotherapy Trial for HPV Positive Oropharyngeal Cancer Initiated
Trial Update
- Surufatinib trial initiated for adjuvant therapy in pancreatic neuroendocrine tumors
Trial Update
- Phase I/IIa Trial of MC1R-targeted Therapy with Nivolumab in Advanced Melanoma
Trial Update
- Study on Image-Guided Cancer Treatments Using Spectral Angio-CT
Trial Update
- Phase II Trial of Venetoclax and Rituximab in Older Patients With Mantle Cell Lymphoma
Trial Update
- Imfinzi+Imjudo shows significant PFS improvement in early liver cancer trial
Trial Update
- TAPUR Study Evaluates Targeted Therapies in Advanced Cancer with Genomic Variants
Trial Update
Related Competitors
Pfizer — Trodelvy
Pressure: medium
Pfizer is a direct competitive threat because it has a discontinued program in Oncology · NSCLC (Trodelvy) and could narrow Merck's development lead — particularly against Trodelvy.
Merck — CMP-001
Pressure: medium
Merck is an emerging emerging competitor with Phase II activity on CMP-001 in Oncology · Melanoma; while behind Bristol Myers Squibb (Phase II), accelerated readouts could compress Bristol Myers Squibb's strategic window.
Merck — CMP-001
Pressure: medium
Merck is an emerging emerging competitor with Phase II activity on CMP-001 in Oncology · Melanoma; while behind Bristol Myers Squibb (Phase II), accelerated readouts could compress Bristol Myers Squibb's strategic window.
Lilly — Calderasib
Pressure: medium
Lilly is a direct competitive threat because it has a Phase III program in Oncology · NSCLC (Calderasib) and could narrow Merck's development lead.
Pfizer — Trodelvy
Pressure: medium
Pfizer is a direct competitive threat because it has a discontinued program in Oncology · NSCLC (Trodelvy) and could narrow Merck's development lead — particularly against Trodelvy.
AstraZeneca — Pipeline activity
Pressure: medium
AstraZeneca is a regulatory competitive threat because recent agency-facing activity on Pipeline activity in Oncology · Prostate Cancer may reset approval benchmarks and timeline expectations for Pfizer.
Merck — CMP-001
Pressure: medium
Merck is an emerging emerging competitor with Phase II activity on CMP-001 in Oncology · Melanoma; while behind Bristol Myers Squibb (Phase II), accelerated readouts could compress Bristol Myers Squibb's strategic window.
Merck — CMP-001
Pressure: medium
Merck is an emerging emerging competitor with Phase II activity on CMP-001 in Oncology · Melanoma; while behind Bristol Myers Squibb (Phase II), accelerated readouts could compress Bristol Myers Squibb's strategic window.
Roche — Pipeline activity
Pressure: high
Roche is a regulatory competitive threat because recent agency-facing activity on Pipeline activity in Oncology · Prostate Cancer may reset approval benchmarks and timeline expectations for Pfizer.
Roche — TALZENNA
Pressure: high
Roche is a regulatory competitive threat because recent agency-facing activity on TALZENNA in Oncology · Prostate Cancer may reset approval benchmarks and timeline expectations for Pfizer.
AstraZeneca — TALZENNA
Pressure: high
AstraZeneca is a regulatory competitive threat because recent agency-facing activity on TALZENNA in Oncology · Prostate Cancer may reset approval benchmarks and timeline expectations for Pfizer.
AstraZeneca — TALZENNA
Pressure: high
AstraZeneca is a regulatory competitive threat because recent agency-facing activity on TALZENNA in Oncology · Prostate Cancer may reset approval benchmarks and timeline expectations for Pfizer.
AstraZeneca — TALZENNA
Pressure: high
AstraZeneca is a regulatory competitive threat because recent agency-facing activity on TALZENNA in Oncology · Prostate Cancer may reset approval benchmarks and timeline expectations for Pfizer.
Related Regulatory Precedents
FDA
July - September 2022 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
July - September 2022 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
SourceFDA
FDA AP — KEYTRUDA (SUPPL)
Application BLA125514. Sponsor: MERCK SHARP DOHME. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: PEMBROLIZUMAB.
SourceFDA
FDA AP — KEYTRUDA QLEX (SUPPL)
Application BLA761467. Sponsor: MERCK SHARP DOHME. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: PEMBROLIZUMAB, BERAHYALURONIDASE ALFA-PMPH.
SourceFDA
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDA is requiring revisions to the Boxed Warning, FDA’s most prominent warning, for Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to include information about the risks of serious heart-related events, cancer, blood clots, and death.
SourceFDA
Sunscreen: How to Help Protect Your Skin from the Sun
How you use sunscreens, and what other protective measures you take, make a difference in how well you are able to protect yourself and your family from sunburn, skin cancer, early skin aging and other risks of overexposure to the sun.
SourceFDA
January - March 2024 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
January - March 2024 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
SourceFDA
October - December 2022 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
SourceFDA
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
SourceFDA
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDA is requiring revisions to the Boxed Warning, FDA’s most prominent warning, for Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to include information about the risks of serious heart-related events, cancer, blood clots, and death.
SourceFDA
Sunscreen: How to Help Protect Your Skin from the Sun
How you use sunscreens, and what other protective measures you take, make a difference in how well you are able to protect yourself and your family from sunburn, skin cancer, early skin aging and other risks of overexposure to the sun.
SourceMHRA
Opportunities for patients and the public to be involved in the work of the MHRA
How we engage and involve patients and the public in our regulatory decision-making.
SourceFDA
FDA AP — KEYTRUDA (SUPPL)
Application BLA125514. Sponsor: MERCK SHARP DOHME. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: PEMBROLIZUMAB.
SourceFDA
FDA AP — KEYTRUDA QLEX (SUPPL)
Application BLA761467. Sponsor: MERCK SHARP DOHME. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: PEMBROLIZUMAB, BERAHYALURONIDASE ALFA-PMPH.
SourceFDA
April - June 2022 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
April - June 2022 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
SourceFDA
October - December 2024 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
October - December 2024 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
SourceFDA
Sunscreen: How to Help Protect Your Skin from the Sun
How you use sunscreens, and what other protective measures you take, make a difference in how well you are able to protect yourself and your family from sunburn, skin cancer, early skin aging and other risks of overexposure to the sun.
SourceFDA
FDA AP — INQOVI (SUPPL)
Application NDA212576. Sponsor: TAIHO ONCOLOGY. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: CEDAZURIDINE, DECITABINE.
SourceFDA
FDA AP — INQOVI (SUPPL)
Application NDA212576. Sponsor: TAIHO ONCOLOGY. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: CEDAZURIDINE, DECITABINE.
SourceFDA
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
SourceFDA
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
SourceFDA
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDA is requiring revisions to the Boxed Warning, FDA’s most prominent warning, for Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to include information about the risks of serious heart-related events, cancer, blood clots, and death.
SourceFDA
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
SourcePMDA
[SHINSA]The new website “Designation / Early Access“ launched.
PMDA document relevant to the signal.
SourceMHRA
Project Orbis
Project Orbis is a programme to review and approve promising cancer drugs helping patients access treatments faster.
SourceMHRA
Risk of severe harm from use of incorrect giving (administration) set for blood transfusion (DSI/2026/003)
There is a potential for serious harm to patients if an intravenous (IV) infusion giving set is used instead of a blood transfusion giving set to deliver a transfusion of blood or blood components.
SourceMHRA
Class 3 Medicines Recall: Aspar Pharmaceuticals Ltd, Ibuprofen 200mg Tablets, Ibucalm 200mg tablets, EL(26)A/07
Aspar Pharmaceuticals Ltd is recalling specific batches distributed in Aspar, Almus and Numark livery. The batches are being recalled as a precautionary measure following findings of foil perforations in some blisters.
SourceFDA
FDA AP — INQOVI (SUPPL)
Application NDA212576. Sponsor: TAIHO ONCOLOGY. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: CEDAZURIDINE, DECITABINE.
SourceFDA
FDA AP — INQOVI (SUPPL)
Application NDA212576. Sponsor: TAIHO ONCOLOGY. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: CEDAZURIDINE, DECITABINE.
SourceFDA
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDA is requiring revisions to the Boxed Warning, FDA’s most prominent warning, for Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to include information about the risks of serious heart-related events, cancer, blood clots, and death.
SourceFDA
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDA is requiring revisions to the Boxed Warning, FDA’s most prominent warning, for Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to include information about the risks of serious heart-related events, cancer, blood clots, and death.
SourceFDA
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDA is requiring revisions to the Boxed Warning, FDA’s most prominent warning, for Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to include information about the risks of serious heart-related events, cancer, blood clots, and death.
SourceFDA
Ongoing | Cancer Accelerated Approvals
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
SourceFDA
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
SourceFDA
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDA is requiring revisions to the Boxed Warning, FDA’s most prominent warning, for Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to include information about the risks of serious heart-related events, cancer, blood clots, and death.
SourceFDA
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
SourceFDA
FDA AP — INQOVI (SUPPL)
Application NDA212576. Sponsor: TAIHO ONCOLOGY. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: CEDAZURIDINE, DECITABINE.
SourceFDA
FDA AP — INQOVI (SUPPL)
Application NDA212576. Sponsor: TAIHO ONCOLOGY. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: CEDAZURIDINE, DECITABINE.
SourceMHRA
Opportunities for patients and the public to be involved in the work of the MHRA
How we engage and involve patients and the public in our regulatory decision-making.
SourceFDA
FDA AP — INQOVI (SUPPL)
Application NDA212576. Sponsor: TAIHO ONCOLOGY. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: CEDAZURIDINE, DECITABINE.
SourceFDA
FDA AP — INQOVI (SUPPL)
Application NDA212576. Sponsor: TAIHO ONCOLOGY. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: CEDAZURIDINE, DECITABINE.
SourceFDA
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
SourceFDA
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDA is requiring revisions to the Boxed Warning, FDA’s most prominent warning, for Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to include information about the risks of serious heart-related events, cancer, blood clots, and death.
SourceFDA
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
SourceFDA
FDA AP — INQOVI (SUPPL)
Application NDA212576. Sponsor: TAIHO ONCOLOGY. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: CEDAZURIDINE, DECITABINE.
SourceFDA
FDA AP — INQOVI (SUPPL)
Application NDA212576. Sponsor: TAIHO ONCOLOGY. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: CEDAZURIDINE, DECITABINE.
SourceFDA
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
SourceFDA
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
SourceMHRA
Draft rare disease therapies regulatory framework
MHRA are seeking feedback on a proposed framework for rare disease therapies.
SourceFDA
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
SourceMHRA
Project Orbis
Project Orbis is a programme to review and approve promising cancer drugs helping patients access treatments faster.
SourceFDA
FDA AP — INQOVI (SUPPL)
Application NDA212576. Sponsor: TAIHO ONCOLOGY. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: CEDAZURIDINE, DECITABINE.
SourceFDA
FDA AP — INQOVI (SUPPL)
Application NDA212576. Sponsor: TAIHO ONCOLOGY. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: CEDAZURIDINE, DECITABINE.
Source